NON-SMALL CELL LUNG CANCER

This early-phase study tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This early-stage trial tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had certain genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study tested whether adding canakinumab to standard chemotherapy and pembrolizumab could help people with advanced non-small cell lung cancer. It included 673 adults who had not received prior treatment. The trial was stopped early, and results are not yet available. This is…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aims to help the body's immune system fight cancer by targeting a protein called PD-1. Some participants received IMU-201 alone, while others got …

This early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The main goals were to check safety and find the right dose. The study was stopped early, so results are limi…

This early-stage study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in 4 adults with advanced solid tumors like lung, bladder, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, s…

This study tested whether giving a higher dose of radiation directly to the main tumor, while keeping standard doses to surrounding areas, is safe for people with non-small cell lung cancer. Six participants received targeted radiation plus standard chemotherapy. The goal was to …

This study tested a new drug called SAR444245 combined with other cancer treatments in 106 adults with advanced non-small cell lung cancer or pleural mesothelioma. The goal was to see if the combination shrank tumors. The trial was terminated early, so final results are limited.

This early-phase study tested whether adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer. Only one person participated before the study was stopped. The goal was to measure immune cell changes in tu…